What's new? Log in Free sign up

Apogee Therapeutics (APGE)

Company Profile

Company profile

Ticker

APGE

Exchange

Website

www.apogeetherapeutics.com

CEO

Michael Thomas Henderson

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • bluebird bio • Acorda Therapeutics ...

Former names

Apogee Therapeutics, LLC

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Apogee Therapeutics Securities Corporation ...

IRS number

880588063

APGE stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Regulation FD Disclosure

Quarterly report

10 Nov 25

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Entry into a Material Definitive Agreement

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Quarterly report

11 Aug 25

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Regulation FD Disclosure

Submission of Matters to a Vote of Security Holders

Latest ownership filings

View all

MICHAEL THOMAS HENDERSON

Carl Dambkowski

Notice of proposed sale of securities

Carl Dambkowski

MICHAEL THOMAS HENDERSON

Notice of proposed sale of securities

Notice of proposed sale of securities

MICHAEL THOMAS HENDERSON

Financial summary

Financial statements Chart APGE financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	107.91 mm	107.91 mm	107.91 mm	107.91 mm	107.91 mm	107.91 mm
Cash burn (monthly)	5.52 mm	930.00 k	23.76 mm	23.62 mm	18.09 mm	19.37 mm
Cash used (since last report)	20.19 mm	3.40 mm	86.85 mm	86.34 mm	66.11 mm	70.82 mm
Cash remaining	87.72 mm	104.51 mm	21.06 mm	21.58 mm	41.81 mm	37.10 mm
Runway (months of cash)	15.9	112.4	0.9	0.9	2.3	1.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

APGE institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	158	143	+10.5%
Opened positions	38	27	+40.7%
Closed positions	23	25	-8.0%
Increased positions	55	48	+14.6%
Reduced positions	39	46	-15.2%

13F shares	Current	Prev Q	Change
Total value	2.54 tn	3.22 tn	-21.2%
Total shares	63.80 mm	62.17 mm	+2.6%
Total puts	71.00 k	259.40 k	-72.6%
Total calls	35.75 k	44.90 k	-20.4%
Total put/call ratio	2.0	5.8	-65.6%

Largest owners	Shares	Value	Change
VR Adviser	8.49 mm	$384.75 bn	0.0%
FMR	7.50 mm	$339.72 bn	-0.0%
Wellington Management	4.52 mm	$204.64 bn	-6.2%
Venrock Healthcare Capital Partners III	3.89 mm	$80.47 mm	0.0%
BLK BlackRock	3.04 mm	$137.94 bn	+2.3%
RTW Investments	2.71 mm	$122.86 bn	+0.0%
Driehaus Capital Management	2.61 mm	$118.02 bn	+2.8%
Access Industries Management	2.19 mm	$120.25 mm	0.0%
Vanguard	2.10 mm	$95.02 bn	-1.4%
Fairmount Funds Management	2.05 mm	$92.80 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Deep Track Capital	0.00	-1.00 mm	EXIT
Perceptive Advisors	1.05 mm	-967.78 k	-48.0%
Siren, L.L.C.	747.33 k	+747.33 k	NEW
Mercer Global Advisors	720.10 k	+720.10 k	NEW
JHG Janus Henderson	1.14 mm	+665.54 k	+141.7%
Waypoint Capital Advisors	0.00	-627.09 k	EXIT
Paradigm Biocapital Advisors	1.28 mm	+581.95 k	+82.9%
JEF Jefferies Financial	887.50 k	+518.30 k	+140.4%
UBS UBS	541.29 k	+489.47 k	+944.6%
Point72 Asset Management	302.74 k	-404.53 k	-57.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

APGE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Jan 26	Michael Thomas Henderson	Common Stock	Sell	Dispose S	No	Yes	83.79	470	39.38 k	1,192,987
14 Jan 26	Michael Thomas Henderson	Common Stock	Sell	Dispose S	No	Yes	83.16	5,386	447.90 k	1,193,457
14 Jan 26	Michael Thomas Henderson	Common Stock	Sell	Dispose S	No	Yes	82.41	1,854	152.79 k	1,198,843
14 Jan 26	Michael Thomas Henderson	Common Stock	Sell	Dispose S	No	Yes	81	2,374	192.29 k	1,200,697
14 Jan 26	Michael Thomas Henderson	Common Stock	Sell	Dispose S	No	Yes	79.82	8,476	676.55 k	1,203,071
14 Jan 26	Michael Thomas Henderson	Common Stock	Sell	Dispose S	No	Yes	78.64	1,440	113.24 k	1,211,547
7 Jan 26	Carl Dambkowski	Common Stock	Sell	Dispose S	No	Yes	80.06	100	8.01 k	212,523
7 Jan 26	Carl Dambkowski	Common Stock	Sell	Dispose S	No	Yes	79.04	826	65.29 k	212,623
7 Jan 26	Carl Dambkowski	Common Stock	Sell	Dispose S	No	Yes	77.9	14,820	1.15 mm	213,449
7 Jan 26	Carl Dambkowski	Common Stock	Sell	Dispose S	No	Yes	77.13	2,954	227.84 k	228,269

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Wolfe Research Initiates Coverage On Apogee Therapeutics with Peer Perform Rating

Wolfe Research analyst Andy Chen initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Peer Perform rating.

One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial

Apogee Therapeutics reports early trial data showing its asthma drug APG777 sharply reduced a key inflammation marker for up to 32 weeks and was well-tolerated in patients.

BTIG Maintains Buy on Apogee Therapeutics, Raises Price Target to $137

BTIG analyst Julian Harrison maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $128 to $137.

BTIG Maintains Buy on Apogee Therapeutics, Raises Price Target to $128

This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Press releases

From Benzinga Pro

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.